Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrin alpha M (CD11b), frequently identified in rodent research via the OX42 monoclonal antibody, is a critical component of the Mac-1 (CD11b/CD18) heterodimeric integrin receptor (Robinson et al., 1986). This molecule is primarily expressed on myeloid-lineage cells, including microglia, macrophages, and neutrophils, where it facilitates cell-cell and cell-matrix interactions (UniProt P11215). The term OX42-positive microglia refers to the activated state of these cells, characterized by the upregulation of CD11b during neuroinflammatory processes (Schmid et al., 2018). CD11b plays a pivotal role in the innate immune system by mediating leukocyte adhesion, transendothelial migration, and the phagocytosis of complement-opsonized pathogens or debris (NCBI Gene: 3684). In various neurodegenerative and inflammatory diseases, such as Alzheimer's disease and stroke, the persistent activation of CD11b-expressing microglia contributes to tissue damage and disease progression. Therapeutic strategies targeting CD11b involve small molecule modulators, such as Leukadherin-1, which aim to stabilize the integrin in specific conformational states to reduce harmful inflammation while maintaining protective immune functions (Schmid et al., 2018). Overall, CD11b serves as both a vital marker for microglial activation and a promising therapeutic target for controlling myeloid-driven pathology.
Allosteric modulation of the Integrin alpha M subunit to regulate myeloid cell adhesion, migration, and phagocytic activity (Schmid et al., 2018).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrin alpha M (CD11b) (ITGAM).